Egfr Sequencing
Egfr Sequencing - Related Videos
05:17
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
0 Views •
2025
This protocol describes an automated, ISO15189-accredited next-generation sequencing workflow for detecting targetable genomic alterations in non-small cell lung cancer (NSCLC) formalin-fixed paraffin-embedded tissues.
08:12
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
0 Views •
Cited by 4 •
2020
The genetically tractable nematode Caenorhabditis elegans can be used as a simple and inexpensive model for drug discovery. Described here is a protocol to identify anticancer therapeutics that inhibit the downstream signaling of RAS and EGFR proteins.
09:38
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
0 Views •
Cited by 4 •
2017
An in vitro method for establishing dual resistance to an EGFR-TKI and a MET-TKI in cancer cells is described. This method is useful for developing treatments for patients with EGFR-mutations, who exhibit disease progression despite EGFR-TKI treatment with MET-amplification. It can also be modified for inhibitors targeting other molecules.
08:57
Amplicon Sequencing using the Long-Read Sequencing Technologies
0 Views •
2025
This protocol was optimized for targeted deep sequencing of 18 drug-resistance regions in Mycobacterium tuberculosis using a long-read sequencing platform, followed by analysis with a tuberculosis-specific bioinformatics pipeline designed for long-read data.
07:30
Optimization for Sequencing and Analysis of Degraded FFPE-RNA Samples
0 Views •
Cited by 19 •
2020
This method describes the steps to improve the quality and quantity of sequence data that can be obtained from formalin-fixed paraffin-embedded (FFPE) RNA samples. We describe the methodology to more accurately assess the quality of FFPE-RNA samples, prepare sequencing libraries, and analyze the data from FFPE-RNA samples.
FAQs
Activating EGFR mutations can connect sequence findings to abnormal cancer signaling. When sequencing identifies such alterations, researchers can relate the genetic change to pathways that promote abnormal cell growth rather than treating the result as an isolated DNA observation. This connection supports tumor classification and helps frame investigations into how altered EGFR biology contributes to cancer behavior.
Because tumor DNA can change during cancer treatment, repeated sequencing may show newly detected or altered variants associated with reduced response to EGFR inhibitors. Comparing sequence results from repeated analyses helps distinguish an initial treatment-relevant alteration from later genetic changes and supports studies aimed at explaining resistance and developing more effective therapies.
Characterization determines more than whether a tumor contains an EGFR difference; it clarifies the alteration identified in the sequence and makes the result useful for interpretation. Researchers can then relate the finding to cancer biology, tumor classification, or investigations of EGFR inhibitor suitability, rather than relying on an unspecified genetic signal.
A practical workflow begins with isolating tumor DNA, followed by amplifying or preparing the EGFR-containing regions. Sequencing then determines their nucleotide order, after which researchers examine the data for variants and characterize them. Separating sample preparation, sequence generation, and interpretation helps organize cancer studies and shows how molecular data become biologically relevant findings.
Researchers may use EGFR sequencing when a cancer study needs molecular information for tumor classification, pathway analysis, or consideration of targeted EGFR inhibitor use. The approach is informative when the research question connects a tumor’s genetic features with abnormal cell growth or treatment decisions. Its value extends from describing tumor biology to supporting treatment-oriented investigation.
Sequence findings can support therapy-development research by revealing genetic changes associated with resistance to EGFR inhibitors. Investigators can compare these changes with original tumor findings, examine how resistance relates to altered cancer biology, and use the evidence to seek more effective therapies. This makes sequencing useful for patient-oriented decisions and broader translational cancer research.